Medy-Tox

At a glance

Medy-Tox filed 47 disclosures in the last 12 months, including 8 insider, 8 5% holder, 4 buyback and 3 earnings. The most recent key filing was on Sep 16.

Revenue for 2025 was ₩247B, up 8.2% on 2024. Operating margin was 6.9% against 8.9% a year earlier. Debt was 28% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩129B and operating profit of ₩12.1B.

The 2025 annual report lists 753 employees with an average tenure of 5.3 years and average pay of ₩64.4M, #785 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩224.8M each on average. It paid ₩1,200 per common share in cash dividends, against ₩1,100 a year earlier (+9.1%). 정현호 and related parties held 17.45% at year end.

From the 2025 annual report

Staff: 753 (401 men, 352 women), of whom 43 on fixed-term contracts. Total pay for the year: ₩48.5B. Directors and auditors: 6, paid ₩1.3B in total.

Dividends (common shares)

Largest shareholder

정현호 holds 17.19%; with 8 related parties the group holds 17.45% of common shares at year end (from 17.40% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary